NCT07821710

Brief Summary

This single-center, 1:1 randomized controlled trial aimed to evaluate the efficacy of infection-site-targeted postural drainage combined with mechanical vibration for mechanically ventilated ICU patients with pulmonary infection. Eligible subjects were randomly assigned to either the personalized-care group (PCG, intervention) or routine-care group (RCG, control). Patients in PCG received imaging-guided infection-site-targeted postural drainage plus mechanical vibration. Patients in RCG received standard routine position changes and mechanical vibration without imaging-guided targeted positional adjustment. The primary outcome was duration of invasive mechanical ventilation. Secondary outcomes included PaO₂/FiO₂ ratio, ICU length of stay, total hospital length of stay, and 28-day all-cause mortality.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
384

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2022

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2024

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

September 10, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 16, 2026

Completed
Last Updated

September 16, 2026

Status Verified

September 1, 2026

Enrollment Period

2.5 years

First QC Date

September 10, 2026

Last Update Submit

September 10, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Duration of mechanical ventilation

    From initiation of invasive mechanical ventilation until successful extubation or death, assessed up to day 28.

Secondary Outcomes (4)

  • 28-day mortality

    All-cause mortality assessed at 28 calendar days from the date of randomization

  • PaO₂/FiO₂ ratio

    Measured at baseline (X1), Day 1, Day 2, Day 3, Day 4 post-randomization (X2-X4), and at weaning preparation (X5), all within 28 calendar days from randomization

  • ICU length of stay

    From randomization until ICU discharge, assessed up to 28 calendar days from randomization

  • Total hospital length of stay

    From randomization until hospital discharge, assessed up to 28 calendar days from randomization

Study Arms (2)

Intervention group

EXPERIMENTAL
Procedure: Imaging-guided infection-site-targeted postural drainage plus mechanical vibration chest physiotherapy.

Routine-care group

ACTIVE COMPARATOR
Procedure: Routine position change combined with mechanical vibration

Interventions

Imaging-guided infection-site-targeted postural drainage combined with mechanical vibration chest physiotherapy. The body position is individually adjusted according to pulmonary infection location shown on imaging examinations to facilitate sputum drainage.

Intervention group

Routine regular position change combined with mechanical vibration chest physiotherapy. No imaging-guided targeted positional adjustment is performed; body position is changed following standard ICU nursing protocol only.

Routine-care group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged 18-80 years old;
  • Admitted to ICU and receiving invasive mechanical ventilation;
  • Clinically confirmed pulmonary infection;
  • Enrolled between May 2022 and October 2024.

You may not qualify if:

  • Unstable systemic disease contraindicating postural changes;
  • Active bleeding (gastrointestinal, intracranial, or pulmonary);
  • Requirement for continuous renal replacement therapy;
  • Raised intracranial pressure;
  • Neuromuscular disorder;
  • Multiple fractures or major trauma;
  • Severe hemodynamic instability;
  • Significant arrhythmias;
  • Severe delirium or altered mental status;
  • Pregnancy or lactation;
  • Currently participating in another interventional clinical trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wuxi Taihu Hospital

Wuxi, Jiangsu, 214003, China

Location

MeSH Terms

Conditions

Respiratory Insufficiency

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Attending Physician

Study Record Dates

First Submitted

September 10, 2026

First Posted

September 16, 2026

Study Start

May 1, 2022

Primary Completion

October 30, 2024

Study Completion

October 30, 2024

Last Updated

September 16, 2026

Record last verified: 2026-09

Data Sharing

IPD Sharing
Will not share

Locations